Mifamurtide (Adjuvant for High-Grade Osteosarcoma, non-US approval)
Treatment for Malignant Neoplasm Of Bone And Articular Cartilage
Typical Dosage: 2 mg liposomal muramyl tripeptide intravenously
Effectiveness
55%
Safety Score
60%
Clinical Trials
15
Participants
2K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
2 mg liposomal muramyl tripeptide intravenously
Time to Effect
Months (during treatment course)
Treatment Duration
48 weeks (twice weekly for 24 weeks, then weekly for 24 weeks)
Evidence Quality
MODERATEConfidence Score
65%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$120,000
Monitoring:$1,000
Side Effect Mgmt:$2,000
Total Annual:$123,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$250,000/QALY
QALYs Gained
0.2
Comparison vs Standard Chemotherapy Alone
Cost Difference
+$123,000/year
More expensive
QALY Difference
+0.20 QALYs
Better outcomes
Dominance
No dominance
Mifamurtide (Adjuvant for High-Grade Osteosarcoma, non-US approval) Outcomes
for Malignant Neoplasm Of Bone And Articular Cartilage
Efficacy Outcomes
Overall Effectiveness
+55%
Common Side Effects
Fever/Chills
+50%
Fatigue
+40%
Headache
+25%
Nausea/Vomiting
+25%
Hypotension
+7%
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov